Vanda Pharmaceuticals (VNDA) : Traders are bullish on Vanda Pharmaceuticals (VNDA) as it has outperformed the S&P 500 by a wide margin of 5.4% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 8.22%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 8.68% in the last 1 week, and is up 8.02% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Vanda Pharmaceuticals (NASDAQ:VNDA): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $12.02 and $11.91 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $12.40. The buying momentum continued till the end and the stock did not give up its gains. It closed at $12.39, notching a gain of 3.16% for the day. The total traded volume was 567,176 . The stock had closed at $12.01 on the previous day.
The stock has recorded a 20-day Moving Average of 8.2% and the 50-Day Moving Average is 11.22%. Vanda Pharmaceuticals, Inc. is up 43.9% in the last 3-month period. Year-to-Date the stock performance stands at 33.08%.
Vanda Pharmaceuticals (VNDA) : The most positive equity analysts on Vanda Pharmaceuticals (VNDA) expects the shares to touch $20, whereas, the least positive believes that the stock will trade at $15 in the short term. The company is covered by 3 Wall Street Brokerage Firms. The average price target for shares are $17 with an expected fluctuation of $2.65 from the mean.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Companys product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. HETLIOZ (tasimelteon) is a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) for which a New Drug Application (NDA) was approved by the United States Food and Drug Administration (FDA). Fanapt (iloperidone) is a product for the treatment of schizophrenia. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is under clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.